View : 105 Download: 0

Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model

Title
Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model
Authors
Bae, Ji YunJun, Kang IlKang, Chang KyungSong, Kyoung-HoChoe, Pyoeng GyunBang, Ji-HwanKim, Eu SukPark, Sang WonKim, Hong BinKim, Nam-JoongPark, Wan BeomOh, Myoung-don
Ewha Authors
배지윤
Issue Date
2019
Journal Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN
0066-4804JCR Link

1098-6596JCR Link
Citation
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY vol. 63, no. 4
Keywords
SAL200Staphylococcus aureusmicephage endolysinpneumonia
Publisher
AMER SOC MICROBIOLOGY
Indexed
SCI; SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
SAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. Lethal pneumonia was established by intranasally administering a methicillin-susceptible (Newman) or methicillin-resistant (LAC) S. aureus strain into BALB/c mice. The mice were treated with a single intranasal administration of SAL200 or phosphate-buffered saline at 2 h after S. aureus infection. The survival rates were recorded until 60 h after the bacterial challenge. The bacterial loads in the lungs and blood, histopathology of lung tissues, and serum cytokine levels were evaluated following the S. aureus challenge. The SAL200-treated group and control group exhibited 90% to 95% and 10% to 40% survival rates, respectively. The bacterial loads in the lungs of the SAL200-treated group were significantly lower by similar to 10-fold than those of the control group as early as 1 h after treatment. Histopathologic recovery of pneumonia was observed in the SAL200-treated mice. The cytokine levels were comparable between groups. These results suggest that direct administration of SAL200 into the lungs could be a potential adjunct treatment against severe pneumonia caused by S. aureus.
DOI
10.1128/AAC.02009-18
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE